History of Drew Quality Group, Inc.


In 2013 Deborah Drew and had been working in the pharmaceutical industry for 23
years. She and some of her fellow engineers and scientists had each spent twenty years
or more working for some of the largest drug companies in America. These men and
women were drawn to working for these companies due to their critical work in
reducing suffering and transforming lives.

But, over time, they had each seen these corporations become more and more
consumed by their need to make an ever-increasing amount of profit for their
stockholders. These professionals felt that the mission of their company's had become
co-opted. Some of the older, low-cost drugs that these companies had produced for
years—drugs that are essential for particular patients—were discontinued to make way
for new, higher-priced patented drugs. As a result, over 70 drugs are in shortage today;
drug pricing is no longer assured, and uncertainty plagues hospitals and clinics across
the country.
On April 2, 2014, Deborah Drew and four of her colleagues founded Drew Quality
Group, Inc.—the first nonprofit 501(c)3 generic drug manufacturing company in the
United States. They are committed to manufacturing a number of the drugs on the
FDA's Drug Shortage List, including those discontinued older drugs that are needed by a
small number of patients for a particular disease or condition. And, when feasible, DQG
will directly compete with those sole manufacturers of a given generic drug who are
taking advantage of their situation and gouging the public.


Drew Quality Group, Inc. Mission

Our mission is to improve society’s health by being a supplier of high-quality generic
drugs, manufactured in the United States, through a diverse and inclusive workforce.
We will comply with Good Manufacturing Practices and establish transparent and
constructive relationships with the FDA and other regulatory agencies. Also, we will
ensure quality by focusing on continuing education for our employees and continuous
improvement through industry collaboration and best practices. Ultimately, our mission
is to provide patients with the highest-quality generic drugs at the lowest possible price.

Why a non-profit?

On the surface, the primary difference between a profit making and a non-profit
enterprise lies in how surpluses or profits are treated. The profit making company exists
to make money and, to the extent that it succeeds in this mission, profits either go to
reward the principals and stockholders or are held as retained earnings. The non-profit
exists to fulfill a mission that usually has little or nothing to do with making money. In
contrast, when the activities of the non-profit generate surplus income, this “positive
fund balance” is either set aside to cover future expenses or used to retire debt. Benefit
does not accrue to principals or shareholders, of which there are none, but to the
organization itself as a resource for enhancing and extending its mission.
The provisions for handling surplus income that define the non-profit model are entirely
consistent with Drew's purpose as an organization, which is to produce the highest
quality generic drugs and sell them at the lowest possible prices, while at the same time
enhancing the lives of the people it employs and the communities in which it operates.